Compare KELYB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | ORIC |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.8M | 861.3M |
| IPO Year | 1994 | 2020 |
| Metric | KELYB | ORIC |
|---|---|---|
| Price | $23.47 | $13.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 853.0 | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | N/A |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $156.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $7.23 |
| 52 Week High | $125.00 | $14.93 |
| Indicator | KELYB | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 63.52 |
| Support Level | $11.66 | $10.45 |
| Resistance Level | $24.78 | $14.14 |
| Average True Range (ATR) | 0.55 | 0.88 |
| MACD | -0.18 | 0.05 |
| Stochastic Oscillator | 72.88 | 83.69 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.